


**Figure S1. Individual change in tumour size from baseline to end-of-treatment MRI**



**Figure S1.** Upper panels: change in cranio-caudal diameter (in millimetres) from baseline to end-of-treatment measurement for individual participants in (A) the lanreotide group and (B) the placebo group. Lower panels: percentage change in tumour volume from baseline to end-of-treatment measurement for individual participants in (C) the lanreotide group and (D) the placebo group. The participant's study number at each bar enables quick cross-referencing between cranio-caudal diameter and tumour volume charts. The dashed horizontal lines denote clinically significant change in tumour size.